Lactobacillus delbrueckii subsp. delbrueckii – LDD01 (DSM 22106)

    Gastroenterology strain | Antipathogenic activity

    Characteristics

    FUNCTIONALITY
    Gaseous colic • Inhibition of E. coli, including toxinogenic O157:H7 • Inhibition of Klebsiella pneumoniae and of different coliforms isolated from colicky infants

    Scientific support

    In vitro studies
    a) Savino F. et al. Antagonistic effect of Lactobacillus strains against gasproducing coliforms isolated from colicky infants. BMC Microbiology 2011, 11:157.
    b) Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J Clin Gastroenterol. 2012;46 Suppl.S29-32.
    c) Mogna L. et al. In Vitro Inhibition of Klebsiella pneumoniae by Lactobacillus delbrueckii subsp. delbrueckii LDD01 (DSM 22106): An Innovative Strategy to Possibly Counteract Such Infections in Humans? J Clin Gastroenterol. 2016 Nov/Dec;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S136-S139.


    Gastroenterology blend | Halitosis

    • Lactobacillus rhamnosus – LR06 (DSM 21981)
    • Lactobacillus pentosus – LPS01 (DSM 21980)
    • Lactobacillus plantarum – LP01 (LMG P-21021)
    • Lactobacillus delbrueckii subsp. delbrueckii – LDD01 (DSM 22106)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    1,2) LR06 3 billion CFU + LPS01 3 billion CFU + LP01 3 billion CFU + LDD01 1 billion CFU 500 million CFU
    3) 1.5 billion CFU per strain

    FUNCTIONALITY
    Gastric barrier function • Improvement of the incidence and severity of bad breath (halitosis)

    Scientific support

    Human clinical trials
    1) Del Piano M. et al. The Innovative Potential of Lactobacillus rhamnosus LR06, Lactobacillus pentosus LPS01, Lactobacillus plantarum LP01 and Lactobacillus delbrueckii subsp. delbrueckii LDD01 to Restore the Gastric
    Barrier Effect” in Patients Chronically Treated with PPIs – a Pilot Study. J Clin Gastroenterol 2010;46:S18-S26.
    2) Del Piano M. et al. Correlation Between Chronic Treatment With Proton Pump Inhibitors (PPIs) and Bacterial Overgrowth in the Stomach – Any Possible Beneficial Role for Selected Lactobacilli? J Clin Gastroenterol
    2014;48:S40-S46.
    3) Del Piano M. et al. Correlation Between Specific Bacterial Groups in the Oral Cavity and the Severity of Halitosis: any Possible Beneficial Role for Selected Lactobacilli? J Gastroint Dig Syst, 2014; 4:197.

    In vitro studies
    a) Mogna L. et al. In Vitro Inhibition of Klebsiella pneumoniae by Lactobacillus delbrueckii subsp. delbrueckii LDD01 (DSM 22106): An Innovative Strategy to Possibly Counteract Such Infections in Humans? J Clin
    Gastroenterol. 2016 Nov/Dec;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S136-S139.
    b) Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different


    Gastroenterology blend | IBD – abdominal surgery – bowel preparation

    • Lactobacillus plantarum – LP01 (LMG P-21021)
    • Lactococcus lactis – LLC02 (DSM 29536)
    • Lactobacillus delbrueckii subsp. delbrueckii – LDD01 (DSM 22106)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    LP01: 1 billion cells. LLC02 800 million cells. LDD01 200 million cells

    FUNCTIONALITY
    Opposing dysbiosis and improving symptoms such as abdominal pain and bloating in patients with Inflammatory bowel diseases, in patients having undergone abdominal surgery and in patients after colonoscopy

    Scientific support

    Human clinical trials
    1) Bonavina L, Arini A, Ficano L, Iannuzziello D, Pasquale L, Aragona SE, Ciprandi G, On Digestive Disorders ISG. Abincol® (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lactobacillus delbrueckii LDD01), an oral nutraceutical, pragmatic use in patients with chronic intestinal disorders. Acta Biomed. 2019 Jul 10;90(7-S):8-12.
    2) Bonavina L, Arini A, Ficano L, Iannuzziello D, Pasquale L, Aragona SE, Ciprandi G, On Digestive Disorders ISG. Post-surgical intestinal dysbiosis: use of an innovative mixture (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lactobacillus delbrueckii LDD01). Acta Biomed. 2019 Jul 10;90(7-S):18-23.
    3) Bonavina L, Ariani A, Ficano L, Iannuzziello D, Pasquale L, Aragona SE, Drago L, Ciprandi G, On Digestive Disorders ISG. Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, and Lactobacillus delbrueckii LDD01) in patients undergoing bowel preparation. Acta Biomed. 2019 Jul 10;90(7-S):13-17.

    In vitro studies
    a) Mogna L. et al. In Vitro Inhibition of Klebsiella pneumoniae by Lactobacillus delbrueckii subsp. delbrueckii LDD01 (DSM 22106): An Innovative Strategy to Possibly Counteract Such Infections in Humans? J Clin
    Gastroenterol. 2016 Nov/Dec;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S136-S139.
    b) Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J Clin Gastroenterol. 2012;46 Suppl.S29-32.


    Urology strain | Antipathogenic activity

    Characteristics

    FUNCTIONALITY
    Inhibition of pathogens E. coli, Klebsiella and gas-producing coliforms

    Scientific support

    In vitro studies
    a) Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
    b) Savino F. et al. Antagonistic effect of Lactobacillus strains against gasproducing coliforms isolated from colicky infants. BMC Microbiology 2011, 11:157.
    c) Mogna L. et al. In Vitro Inhibition of Klebsiella pneumoniae by Lactobacillus delbrueckii subsp. delbrueckii LDD01 (DSM 22106): An Innovative Strategy to Possibly Counteract Such Infections in Humans? J Clin Gastroenterol. 2016 Nov/Dec;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S136-S139.


    Gut-brain blend | ALS

    • Lactobacillus fermentum – LF10 (DSM 19187)
    • Lactobacillus delbrueckii subsp. delbrueckii – LDD01 (DSM 22106)
    • Lactobacillus plantarum – LP01 (LMG P-21021)
    • Lactobacillus salivarius – LS03 (DSM 22776)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    LF10 4 billion cfu + LDD01 2 billion cfu + LP01 2 billion cfu + LS03 2 billion cfu

    Scientific support

    Human clinical trial
    Mazzini L. et al. Potential Role of Gut Microbiota in ALS Pathogenesis and Possible Novel Therapeutic Strategies. J Clin Gastroenterol, Vol 00, N 00, 2018.

    Clinical studies on-going


    Oral care blend | Halitosis

    • Lactobacillus rhamnosus – LR06 (DSM 21981)
    • Lactobacillus pentosus – LPS01 (DSM 21980)
    • Lactobacillus plantarum – LP01 (LMG P-21021)
    • Lactobacillus delbrueckii subsp. delbrueckii – LDD01 (DSM 22106)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    1.5 billion CFU + 1.5 billion CFU + 1.5 billion CFU + 500 million CFU

    FUNCTIONALITY
    Restoration of a healthy oral flora • Improvement of the incidence and severity of bad breath (halitosis) • Inhibition of pathogens and Volatile Sulphur Compounds producing bacteria

    Scientific support

    Human clinical trial
    Del Piano M. et al. Correlation between specific bacterial groups in the oral cavity and the severity of halitosis: any possible beneficial role for selected Lactobacilli? J Gastroint Dig Syst, 2014; 4:197.

    In vitro studies
    a) Mogna L. et al. In Vitro Inhibition of Klebsiella pneumoniae by Lactobacillus delbrueckii subsp. delbrueckii LDD01 (DSM 22106). An Innovative Strategy to Possibly Counteract Such Infections in Humans? J Clin Gastroenterol, Vol 50, Supp. 2, November/December 2016.
    b) Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains (LP01, LP02, LR04, LR06, LPS01, LDD01, BR03, B632). J Clin Gastroenterol. 2012; 46 Suppl:S29-32.

    + Internal data on immunomodulation, anti-oxidant activity and epithelial barrier effect (TEER in Caco2 cells) available upon request for some of these strains